AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19082870 — intervention group
Group type: COMPARATOR
Intervention: Comparison of prospective versus retrospective ECG-gating
Number of subjects: 100
Study 19082870 — intervention group
Group type: COMPARATOR
Intervention: Protocol D vs Protocol E
Number of subjects: 100
Study 19082870 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of CTDI(vol) and heart rate for protocol A
Number of subjects: 100
Study 19082870 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of CTDI(vol) and heart rate for protocol B
Number of subjects: 100
Study 19082870 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean image noise across all protocols
Number of subjects: 100
Study 19082870 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of image noise with body weight
Number of subjects: 100
Study 19082870 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of image noise with BMI
Number of subjects: 100
Study 17242321 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily SSRI use
Number of subjects: 5008
Study 15655141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox shampoo twice weekly
Number of subjects: 1000
Study 15655141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox shampoo once weekly
Number of subjects: 1000
Study 15655141 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 1000
Study 15655141 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ciclopirox once weekly
Number of subjects: 1000
Study 15655141 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ciclopirox once every 2 weeks
Number of subjects: 1000
Study 15655141 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control) for prophylaxis
Number of subjects: 1000
Study 15655141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox shampoo (both treatment and prophylaxis)
Number of subjects: 1000
Study 12106522 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 112
Study 12106522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 9527938 — intervention group
Group type: EXPERIMENTAL
Intervention: sucrose‐dipped pacifier
Number of subjects: 80
Study 9527938 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA analgesic cream
Number of subjects: 80
Study 9527938 — intervention group
Group type: EXPERIMENTAL
Intervention: sucrose and EMLA combination
Number of subjects: 80
Study 9527938 — intervention group
Group type: EXPERIMENTAL
Intervention: sucrose alone
Number of subjects: 80
Study 9527938 — intervention group
Group type: COMPARATOR
Intervention: control (water‐dipped pacifier only)
Number of subjects: 80
Study 7874096 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg three times daily
Number of subjects: 1
Study 7874096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 2231096 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional steroid therapy, 1000 mg/day for 3 days (group 1)
Number of subjects: 663
Study 2231096 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional steroid therapy, 500 mg/day for 3 days (group 2)
Number of subjects: 663
Study 2231096 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional steroid therapy, 250 mg/day for 3 days (group 3)
Number of subjects: 663
Study 412015 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer aided monitoring system
Number of subjects: 810
Study 31319789 — intervention group
Group type: EXPERIMENTAL
Intervention: Readiness Assessment for Pragmatic Trials (RAPT) model
Number of subjects: 30
Study 31319789 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPT scoring guidelines
Number of subjects: 30
Study 28185976 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral glibenclamide daily for 10 days, n = 29
Number of subjects: 66
Study 28185976 — intervention group
Group type: COMPARATOR
Intervention: Placebo in the same dosage, n = 23
Number of subjects: 66
Study 25956661 — intervention group
Group type: EXPERIMENTAL
Intervention: Tavaborole topical solution, 5%
Number of subjects: 0
Study 25956661 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 22998386 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil mouth rinse (Listerine(®) Coolmint; Johnson & Johnson) used twice per day as an adjunct to mechanical plaque control.
Number of subjects: 50
Study 22998386 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouth rinse used twice per day as an adjunct to mechanical plaque control.
Number of subjects: 50
Study 21080030 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of triads with one, two, or all three categories represented on each trial.
Number of subjects: 0
Study 21080030 — intervention group
Group type: EXPERIMENTAL
Intervention: Context items' category membership explicitly identified.
Number of subjects: 0
Study 21080030 — intervention group
Group type: EXPERIMENTAL
Intervention: Variations in learners' prior knowledge of the relationship between the target and context items.
Number of subjects: 0
Study 20635735 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy (AT)
Number of subjects: 3871
Study 17266173 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin E supplementation (1200 mg/day)
Number of subjects: 10
Study 17266173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15335114 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-actuated nebulizer (BAN)
Number of subjects: 72
Study 15335114 — intervention group
Group type: COMPARATOR
Intervention: Constant-flow nebulizer (CFN)
Number of subjects: 72
Study 11174476 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol (Menorest) at dosages of 25, 50, 75, or 100 microg/d for 3 years
Number of subjects: 325
Study 11174476 — intervention group
Group type: COMPARATOR
Intervention: Switch to 17beta-estradiol (Menorest) at dosages of 25, 50, 75, or 100 microg/d after 2 years of placebo
Number of subjects: 325
Study 11174476 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosage groups of 17beta-estradiol (Menorest)
Number of subjects: 325
Study 11174476 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol (Menorest)
Number of subjects: 325
Study 9641566 — intervention group
Group type: EXPERIMENTAL
Intervention: Local nasal immunotherapy (LNIT)
Number of subjects: 0
Study 9641566 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SIT)
Number of subjects: 0
Study 7653756 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin bolus 3.5 micrograms.kg‐1 intravenously plus an infusion of somatostatin 3.5 micrograms.kg‐1.h‐1
Number of subjects: 40
Study 7653756 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride 0.9% as a placebo
Number of subjects: 40
Study 7653756 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Somatostatin and Control)
Number of subjects: 40
Study 2671362 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% butoconazole vaginal cream for three days
Number of subjects: 271
Study 2671362 — intervention group
Group type: COMPARATOR
Intervention: 2% miconazole vaginal cream for seven days
Number of subjects: 271
Study 791471 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil during postoperative follow-up
Number of subjects: 1118
Study 791471 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1118
Study 30995458 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (walking/jogging on a motor driven treadmill at approximately 70% of age-predicted maximum heart rate)
Number of subjects: 0
Study 30995458 — intervention group
Group type: COMPARATOR
Intervention: Active control (walking on the treadmill at 0.5 mph and 0% grade)
Number of subjects: 0
Study 28592573 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg once daily)
Number of subjects: 120
Study 28592573 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 120
Study 28592573 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (interval training, 5 days a week, 30 min per session)
Number of subjects: 120
Study 28592573 — intervention group
Group type: COMPARATOR
Intervention: Control (lifestyle advice)
Number of subjects: 120
Study 26089656 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based, computer-tailored self-management intervention
Number of subjects: 1325
Study 26089656 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 1325
Study 22967275 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge drinking
Number of subjects: 263
Study 21906647 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59®-adjuvanted quadrivalent influenza vaccine (QIV)
Number of subjects: 480
Study 21906647 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccines (TIV)
Number of subjects: 480
Study 21906647 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59® adjuvant
Number of subjects: 480
Study 21906647 — intervention group
Group type: EXPERIMENTAL
Intervention: Different combinations of adjuvanted (ATIV) and non‐adjuvanted TIV and QIV
Number of subjects: 480
Study 19193652 — intervention group
Group type: EXPERIMENTAL
Intervention: Lo-Pro GlideScope (LP-G)
Number of subjects: 28
Study 19193652 — intervention group
Group type: COMPARATOR
Intervention: Flexible bronchoscope (FB)
Number of subjects: 28
Study 19193652 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue pull
Number of subjects: 28
Study 19193652 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw thrust with tongue pull
Number of subjects: 28
Study 16352680 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 45
Study 16352680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 15172398 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 122
Study 15172398 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 122
Study 10794844 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline brain volumes of the anteromedial temporal lobe (hippocampus and parahippocampal gyrus) and global atrophy index
Number of subjects: 46
Study 10794844 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline medial occipitotemporal and combined middle and inferior temporal gyri
Number of subjects: 46
Study 10794844 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 46
Study 10794844 — intervention group
Group type: COMPARATOR
Intervention: APOE epsilon4 genotype
Number of subjects: 46
Study 8780545 — intervention group
Group type: EXPERIMENTAL
Intervention: RT only
Number of subjects: 199
Study 8780545 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + A (RT + castration)
Number of subjects: 199
Study 8780545 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 199
Study 8780545 — intervention group
Group type: EXPERIMENTAL
Intervention: RT only in patients < 70 years
Number of subjects: 199
Study 8780545 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + A in patients < 70 years
Number of subjects: 199
Study 8780545 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 70-74 years
Number of subjects: 199
Study 8780545 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients older than 74 years
Number of subjects: 199
Study 1961649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified conventional treatment (n = 44)
Number of subjects: 96
Study 1961649 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment (n = 52)
Number of subjects: 96
Study 1961649 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary loss
Number of subjects: 96
Study 1961649 — intervention group
Group type: EXPERIMENTAL
Intervention: Leakage
Number of subjects: 96
Study 6119495 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% glyceryl trinitrate ointment
Number of subjects: 17
Study 6119495 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lanolin)
Number of subjects: 17
Study 31596228 — intervention group
Group type: EXPERIMENTAL
Intervention: Salted mud
Number of subjects: 15
Study 31596228 — intervention group
Group type: EXPERIMENTAL
Intervention: As is mud
Number of subjects: 15
Study 31596228 — intervention group
Group type: EXPERIMENTAL
Intervention: Over‐the‐Shelf mud
Number of subjects: 15
Study 31596228 — intervention group
Group type: COMPARATOR
Intervention: Untreated forearm
Number of subjects: 15
Study 28651207 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT)
Number of subjects: 90
Study 28651207 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 90
Study 28651207 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (MCT and CBT)
Number of subjects: 90
Study 26466081 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous time course trial
Number of subjects: 8
Study 25086153 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended Learning (BL)
Number of subjects: 81
Study 25086153 — intervention group
Group type: COMPARATOR
Intervention: Traditional Learning
Number of subjects: 81
Study 20709514 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve replacement/repair surgery
Number of subjects: 50
Study 20709514 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 50
Study 20814331 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 1-mg single oral dose
Number of subjects: 71
Study 18061060 — intervention group
Group type: EXPERIMENTAL
Intervention: Test vaccine (inactivated candidate vaccine for JEV)
Number of subjects: 867
Study 18061060 — intervention group
Group type: COMPARATOR
Intervention: Licensed vaccine (mouse‐brain‐derived vaccine)
Number of subjects: 867
Study 18061060 — intervention group
Group type: EXPERIMENTAL
Intervention: Test vaccine
Number of subjects: 867
Study 18061060 — intervention group
Group type: COMPARATOR
Intervention: Licensed vaccine
Number of subjects: 867
Study 16283239 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15‐45 mg/day)
Number of subjects: 1269
Study 16283239 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide (80‐320 mg/day)
Number of subjects: 1269
Study 16283239 — intervention group
Group type: COMPARATOR
Intervention: Metformin (850‐2,550 mg/day)
Number of subjects: 1269
Study 12297475 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose mitomycin C (MMC) 2-4 mg, 4-6 mg, or 6-8 mg depending on tumor size
Number of subjects: 36
Study 12297475 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy regimen: 10 mg MMC, 40 mg PI, 300 mg CBP
Number of subjects: 36
Study 10416522 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone for 14 days
Number of subjects: 20
Study 10416522 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 20
Study 8789588 — intervention group
Group type: EXPERIMENTAL
Intervention: Methysergide
Number of subjects: 10
Study 8789588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8789588 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt
Number of subjects: 10
Study 8789588 — intervention group
Group type: EXPERIMENTAL
Intervention: Presyncopal symptoms
Number of subjects: 10
Study 2917676 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied betamethasone-17-valerate (0.1% solution and cream) applied twice daily for 7 days
Number of subjects: 47
Study 2917676 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied betamethasone-17-valerate (0.1% solution and cream) applied twice daily for 14 days
Number of subjects: 47
Study 4393346 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol
Number of subjects: 9
Study 4393346 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 9
Study 31432510 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon catheter (50-mL for 12 hours)
Number of subjects: 204
Study 31432510 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (low-dose infusion)
Number of subjects: 204
Study 31432510 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon catheter
Number of subjects: 204
Study 31432510 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 204
Study 30599916 — intervention group
Group type: EXPERIMENTAL
Intervention: Achillea millefolium 250 mg/day
Number of subjects: 75
Study 30599916 — intervention group
Group type: EXPERIMENTAL
Intervention: Achillea millefolium 500 mg/day
Number of subjects: 75
Study 30599916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 29231586 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (2-3 times per week, total of 14 treatments)
Number of subjects: 44
Study 29231586 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 44
Study 25248340 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram
Number of subjects: 34
Study 23881337 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural therapy
Number of subjects: 51
Study 23881337 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 51
Study 21199997 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory blood pressure monitoring during usual sodium intake
Number of subjects: 46
Study 19816812 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean dietary pattern (MDP) within a hypocaloric diet
Number of subjects: 41
Study 19816812 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher adherence to MDP during nutritional intervention
Number of subjects: 41
Study 19816812 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in Mediterranean diet score from baseline
Number of subjects: 41
Study 21546491 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% human albumin (ALB) administered intravenously at 2 g/kg within 5 hours of stroke onset
Number of subjects: 434
Study 21546491 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 434
Study 21546491 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% human albumin (ALB) administered intravenously at 2 g/kg within 5 hours of stroke onset (among thrombolyzed subjects)
Number of subjects: 434
Study 21546491 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group, among thrombolyzed subjects)
Number of subjects: 434
Study 16048138 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (10 g orally twice per day for 6 days, then 5 g daily)
Number of subjects: 8
Study 16048138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 16048138 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 8
Study 12351464 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) spray for 4 weeks
Number of subjects: 22
Study 12351464 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray for 4 weeks
Number of subjects: 22
Study 9840334 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% oxygen enrichment during sleep
Number of subjects: 18
Study 9840334 — intervention group
Group type: COMPARATOR
Intervention: Ambient air during sleep
Number of subjects: 18
Study 8010550 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral magnesium sulfate (MgSO4)
Number of subjects: 15
Study 8010550 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 15
Study 8010550 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MgSO4-digoxin therapy
Number of subjects: 15
Study 2470988 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline 130 mg every 12 h
Number of subjects: 20
Study 2470988 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline 160 mg every 12 h
Number of subjects: 20
Study 2470988 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine 300 mg every 6 h
Number of subjects: 20
Study 2470988 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine 400 mg every 6 h
Number of subjects: 20
Study 2470988 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline
Number of subjects: 20
Study 2470988 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 20
Study 11763992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and furosemide administered in the morning (05:00)
Number of subjects: 22
Study 11763992 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and furosemide administered in the evening (17:00)
Number of subjects: 22
Study 11763992 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ondansetron
Number of subjects: 22
Study 11763992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and furosemide (both morning and evening)
Number of subjects: 22
Study 11763992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and furosemide in the evening (second course)
Number of subjects: 22
Study 11763992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and furosemide in the first course (morning)
Number of subjects: 22
Study 11763992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and furosemide in the second course (evening)
Number of subjects: 22
Study 11763992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and furosemide in the second course (morning)
Number of subjects: 22
Study 31621054 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidofludimus
Number of subjects: 241
Study 31621054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 28440016 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Transitional Intervention in Psychiatry (STeP)
Number of subjects: 29
Study 28440016 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard discharge process)
Number of subjects: 29
Study 27389036 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated RT (respiratory monitoring)
Number of subjects: 130
Study 27389036 — intervention group
Group type: COMPARATOR
Intervention: Free-breathing RT
Number of subjects: 130
Study 24885140 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted 4-stage approach (4-SA)
Number of subjects: 256
Study 24885140 — intervention group
Group type: COMPARATOR
Intervention: Control group (instructor-led 4-SA)
Number of subjects: 256
Study 21925823 — intervention group
Group type: EXPERIMENTAL
Intervention: VHS/DVD plus printed booklet
Number of subjects: 187
Study 21925823 — intervention group
Group type: COMPARATOR
Intervention: Booklet alone
Number of subjects: 187